Oracle is to purchase Relsys International, a maker of drug safety and risk management software.
The deal is expected to close in the first half of this year. Terms were not disclosed.
Many of the world's largest pharmaceutical companies use Relsys' software, which is used to track and analyse safety-related data.
Relys will "bring significant domain knowledge and experience" to Oracle's health sciences global business unit, Oracle says.
Oracle's move "makes a lot of sense" given the political climate in the US, says Redmonk analyst James Governor.
"Healthcare is one of the verticals set to benefit from any big initiatives to fix US healthcare," Governor says.